Современные концепции стратификации кардиоваскулярного риска

Е.А. Григоренко, Н.П. Митьковская, Е.А. Лазарь УО «Белорусский государственный медицинский университет»

2013 №2 | Клинический обзор

Аннотация

Список литературы

В статье изложены основные подходы к стратификации кардиоваскулярного риска при различных коморбидных состояниях. Отражена эволюция представлений об индивидуальном и популяционном рисках. Сделан акцент на факторах риска у реципиентов трансплантатов органов, приведены способы прогнозирования развития неблагоприятных осложнений после проведенной трансплантации. Определены основные направления научных исследований по изучению и стратификации кардиоваскулярного риска.

Ключевые слова:

кардиоваскулярный риск, факторы риска, прогноз осложнений, трансплантация органов

Modern conceptions of cardiovascular risk stratification

The paper states basic approaches to the stratification of cardiovascular risk in various co-morbid conditions. The evolution of ideas about individual and population risks is reflected. An emphasis is made on risk factors in recipients of transplant organs, ways of predicting development of unfavorable complications after a transplant surgery are listed. The main guidelines of research on the study and stratification of cardiovascular risk are outlined.

Keywords

cardiovascular risk, risk factors, prediction of complications, transplantation of organs

1. Campbell, N. R., Khan N.A., Grover S.A. Barriers and remaining questions on assessment of absolute cardiovascular risk as a starting point for interventions to reduce cardiovascular risk // J. Hypertens. - 2006. - № 24 (9). - Р. 1683-1685.
2. Pyorala, K., De Backer G., Graham I. et al. Prevention of coronary heart disease in clinical practice: recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension // Eur. Heart J. - 1994. - № 15 (10). - P. 1300-1331.
3. Wood, D., De Backer G., Faergeman O. et al. Prevention of coronary heart disease in clinical practice. Summary of recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention // Blood Press. - 1998. - № 7(5-6). - P. 262-269.
4. De Backer, G., Ambrosioni E., Borch-Johnsen K. et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice // Eur. Heart J. - 2003. - № 24(17). - P. 1601-1610.
5. Jardine, A. G., Gaston R. S., Fellstrom B.C. et al. Prevention of cardiovascular disease in adult recipients of kidney transplants // Lancet. - 2011. - № 378 (9800). - P. 1419-1427.
6. Israni, A. K., Snyder J. J., Skeans M. A. et al. Predicting coronary heart disease after kidney transplantation: Patient Outcomes in Renal Transplantation (PORT) Study // Am. J. Transplant. - 2010. - № 10(2). - P. 338-353.
7. Kasiske, B.L., Zeier M.G., Chapman J. R. etal. KDIGO clinical practice guideline for the care of kidney transplant recipients // Am. J. Transplant. -2009. - № 9 (Suppl. 3). - 155 p.
8. Lentine, K. L„ Costa S. P., Weir M. R. et al. Cardiac Disease Evaluation and Management Among Kidney and Liver Transplantation Candidates: A Scientific Statement From the American Heart Association and the American College of Cardiology Foundation // Circulation. - 2012. - № 126. - P. 617-663.
9. Conroy, R. M., Pyorala K., Fitzgerald, A.P. etal. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project // Eur. Heart J. - 2003. - № 24 (11). - P. 987-1003.
10. Lloyd-Jones, D. M„ Dyer A. R„ Wang R. et al. Risk factor burden in middle age and lifetime risks for cardiovascular and non-cardiovascular death (Chicago Heart Association Detection Project in Industry) // Am. J.Cardiol. - 2007. - № 99(4). - P. 535-540.
11. European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension / / J . Hypertens. - 2003. - № 21(6). - P. 1011-1053.
12. Whitworth. J. A., World Health Organization, International Society of Hypertension Writing Group.2003 World Health Organization (WHO) / International Society of Hypertension (ISH) statement on management of hypertension//J. Hypertens. - 2003,- № 21(11). - P. 1983-1992.
13. Jennings, G, Wong J. Regression of Left ventricular hypertrophy in hypertension: changing patterns with successive meta-analysis // J. Hypertens. Suppl. - 1998. - № 16ю - P. 29-34.
14. Vakili, B. A., Okin P.M., Devereux R.B. Prognostic implications of left ventricular hypertrophy // Am. Heart J. - 2001. - № 141 (3). - P. 334-341.
15. Palmieri, V., Devereux R. В., Hollywood J. Association of pulse pressure with cardiovascular outcome is independent of left ventricular hypertrophy and systolic dysfunction: the Strong Heart Study // Am. J. Hypertens. - 2006. - № 19 (6). - P. 601-607.
16. Gerdts, E„ Wachtell K„ Omvik P. et al. Left atrial size and risk of major cardiovascular events during antihypertensive treatment: losartan intervention for endpoint reduction in hypertension trial // Hypertension. -2007. - № 49 (2). - P. 311-316.
17. DeSimone, G., Palmieri V., Koren M. J. etal. Prognostic implications of the compensatory nature of left ventricular mass in arterial hypertension // J . Hypertens. - 2001. - № 19 (1). - P. 119-125.
18. Verdecchia, P., Angeli F., Pittavini L. et al. Regression of left ventricular hypertrophy and cardiovascular risk changes in hypertensive patients// Ital. Heart J. - 2004. - № 5 (7). - P. 505-510.
19. Mancia, G. Total cardiovascular risk: a new treatment concept// J. Hypertens. Suppl. - 2006. - № 24 (2). - P. 17-24.
20. Lee, K. W., Lip G. Y. Insulin resistance and vascular remodelling, in relation to left ventricular mass, geometry and function: an answer to LIFE? / / J . Hum. Hypertens. - 2003. - № 17 (5). - P. 299-304.
21. Willerson, J. Т., Ridker P.M. Inflammation as a cardiovascular risk factor//Circulation. - 2004. - № 109 (21. Suppl. 1). - P. 112-110.
22. Ridker, P.M., Rifai N.. Rose L. et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events // N. Engl. J. Med. - 2002. - № 347 (20). - P. 1557-1565.
23. Blake, G. J., Rifai, N.. Buring, J.E. Blood pressure, C-reactive protein, and risk of future cardiovascular events // Circulation. - 2003. -№ 108 (24). - P. 2993-2999.
24. Yarnell, J. W„ Patterson С. C„ Sweetnam P. M. etal. Haemostatic / inflammatory markers predict 10-year risk of IHD at leastas well as lipids: the Caerphilly collaborative studies // Eur. Heart J. - 2004. - № 25 (12).-P. 1049-1056.
25. Pearson, T. A. New tools for coronary risk assessment: what are their advantages and limitations? // Circulation. - 2002. - № 105 (7). - P. 886-892.
26. Morange, P. E., Simon C., Alessi M.C. etal. Endothelial cell markers and the risk of coronary heart disease: the Prospective Epidemiological Study of Myocardial Infarction (PRIME) s t u d y / / Circulation. - 2004. - № 109 (11). - P. 1343-1348.
27. Yusuf, S., Hawken S., Ounpuu S. et al. Effect of potentially modifiable riskfactors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control s t u d y / / Lancet. - 2004. - № 364 (9438). - P. 937-952.
28. Weiner, D. E„ Tighiouart H., Elsayed E. F. et al. The Framingham predictive instrument in chronic kidney disease // J. Am. Coll. Cardiol. -2007. - № 50 (3). - P. 217-224.
29. S атак, M. J., Levey A. S„ Schoolwerth A. C. etal. Kidney disease as a riskfactor for development of cardiovascular disease: a statementfrom the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention // Circulation. - 2003. - № 108 (17). - P. 2154-2169.
30. Go, A. S„ Chertow G. M., Fan D. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization // N. Engl. J. Med. - 2004. - № 351 (13). - P. 1296-1305.
31. Weiner, D.E., Carpenter M.A., Levey A.S. etal. Kidney function and risk of cardiovascular disease and mortality in kidney transplant recipients: the FAVORIT trial // Am. J. Transplant. - 2012,- № 12 (9). - P. 2437-2445.
32. Fernandez-Fresnedo, G., Escallada R„ Rodrigo E. etal. The risk of cardiovascular disease associated with proteinuria in renal transplant patients//Transplantation. - 2002. - № 73 (8). - P. 1345-1348.
33. Kasiske, B. L., Snyder, J. J., Gilbertson, D. Diabetes mellitus after kidney transplantation in the United States / / A m . J. Transplant. - 2003. - № 3 (2). - 178-185.